<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00876655</url>
  </required_header>
  <id_info>
    <org_study_id>1986-025</org_study_id>
    <secondary_id>TR701-108</secondary_id>
    <nct_id>NCT00876655</nct_id>
  </id_info>
  <brief_title>Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate</brief_title>
  <official_title>An Open-Label, Randomized, Single-Dose, 2-Treatment, 2-Sequence, Crossover, Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of TR-701 (Torezolid Phosphate) in Normal Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trius Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trius Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK)
      of 2 different TR-701 oral formulations (free acid phosphate powder in capsule and di-sodium
      phosphate salt formulated capsule) after single doses in normal healthy adult subjects and to
      assess the relative bioavailability of TR-701 free acid phosphate powder in capsule
      formulation compared to di-sodium phosphate salt formulated capsule.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive the following treatments in a crossover design:

      Treatment A (Reference): One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to
      150 mg TR-700) administered orally after at least an 8-hour fast with 240 mL room temperature
      water;

      Treatment B (Test): One 182 mg capsule of TR-701 free acid phosphate (equivalent to 150 mg
      TR-700) administered orally after at least an 8-hour fast with 240 mL room temperature water;

      Descriptive statistics will be calculated for PK parameters including Cmax, Tmax, AUC0-t, and
      AUC0-inf.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetics and relative bioavailability of TR-701 free acid phosphate powder in capsule formulation compared to di-sodium phosphate salt formulated capsule after single doses in normal healthy adult subjects</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the safety and tolerability of 2 different TR-701 oral formulations (free acid phosphate powder in capsule and di-sodium phosphate salt formulated capsule) after single doses in normal healthy adult</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>free acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TR-701 free acid phosphate powder in capsule formulation (equivalent to 150 mg TR-700)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>di-sodium phosphate salt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 di-sodium phosphate salt</intervention_name>
    <description>One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)</description>
    <arm_group_label>di-sodium phosphate salt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 free acid phosphate</intervention_name>
    <description>One 182 mg capsule of TR-701 free acid phosphate (equivalent to 150 mg TR-700)</description>
    <arm_group_label>free acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health, determined by no clinically significant findings from medical history,
             physical examination, 12-lead ECG, and vital signs;

          -  Females will be non-pregnant, non-lactating, and either postmenopausal for at least 1
             year, surgically sterile for at least 90 days, or agree to use an acceptable form of
             contraception

          -  BMI of 18.5 to 32.0 kg/m2, inclusive

        Exclusion Criteria:

          -  Significant history or clinical manifestation of any significant metabolic, allergic,
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,
             gastrointestinal, neurological, or psychiatric disorder

          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound,
             food, or other substance

          -  Pregnancy, lactation, or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David C Carter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance CRU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2009</study_first_submitted>
  <study_first_submitted_qc>April 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2009</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torezolid phosphate</mesh_term>
    <mesh_term>Torezolid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

